There’s been a lot of hype around new Hep C drugs (cough, Gilead, cough), but less attention’s paid to Hepatitis B, a stunningly prevalent version of the virus that can lead to cirrhosis and liver cancer.
Novira Therapeutics just raised $9 million in debt from 10 investors, according to a regulatory filing. The startup last year raised a $25 million Series A, with investors that included Versant Ventures, 5AM Ventures and Canaan Partners.
The company’s NVR 3-778 antiviral is a small molecule drug that inhibits the Hep B core or capsid protein. It recently released Phase 1b trial info, which showed that Novira’s lead candidate was well-tolerated in 40 subjects.
How Artera is Using Agentic AI to Humanize Patient Care
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
About one third of the world’s population is infected with Hep B, according to the World Health Organization; about 5 percent have a chronic form of the disease. The infection leads to more than 1 million deaths per year, the WHO says.